Indirect treatment comparison of bevacizumab + interferon-α-2a vs tyrosine kinase inhibitors in first-line metastatic renal cell carcinoma therapy

BACKGROUND: The vascular endothelial growth factor inhibitor bevacizumab (BEV) given in combination with interferon-α-2a (IFN), and the tyrosine kinase inhibitors (TKIs) sunitinib (SUN) and pazopanib (PAZ), have all shown significant increase in progression-free survival (PFS) in first-line metastat...

Descripción completa

Detalles Bibliográficos
Autores principales: Mickisch, Gerald HJ, Schwander, Björn, Escudier, Bernard, Bellmunt, Joaquim, Maroto, José P, Porta, Camillo, Walzer, Stefan, Siebert, Uwe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2011
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3169982/
https://www.ncbi.nlm.nih.gov/pubmed/21935329
http://dx.doi.org/10.2147/CEOR.S16118

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3169982/
https://www.ncbi.nlm.nih.gov/pubmed/21935329
http://dx.doi.org/10.2147/CEOR.S16118

Ejemplares similares